Literature DB >> 25820158

Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease.

Grazyna Bochenek1, Krystyna Szafraniec2, Joanna Kuschill-Dziurda3, Ewa Nizankowska-Mogilnicka3.   

Abstract

BACKGROUND: Effective control of asthma is the primary goal of its treatment. Despite an improved understanding of asthma pathogenesis and accessibility of novel therapies, the rate of uncontrolled asthma remains high.
OBJECTIVE: To find potential factors associated with asthma control in patients with aspirin-exacerbated respiratory disease (AERD).
METHODS: Clinical data were collected from a specifically structured questionnaire. Demographics, a history of upper airway symptoms, asthma course, exacerbations expressed as emergency department (ED) visits/hospitalizations, and asthma treatment were considered. Spirometry, skin prick tests, total IgE concentration, and blood eosinophil count were evaluated. Asthma control was assessed through the Asthma Control Test (ACT).
RESULTS: Out of 201 AERD patients, 41 (20.4%), 69 (34.3%), and 91 (45.3%) had controlled, partially controlled, and uncontrolled asthma, respectively. A multivariate ordered logistic regression analysis revealed that hospitalizations for asthma in the previous 12 months (OR 2.88; 95%CI, 1.11-7.46), ED visits for asthma throughout its duration (OR 1.05; 95%CI, 1.004-1.10), and total IgE concentration (OR 1.28; 95%CI, 1.02-1.60) were positively associated with poor asthma control, whereas FEV1 values (OR 0.98; 95%CI, 0.96-0.99) and medical care at a referential specialty clinic (OR 0.50; 95%CI, 0.27-0.95) were positively associated with good asthma control.
CONCLUSIONS: The prevalence of uncontrolled asthma in AERD patients is high and similar to that observed in different asthmatic populations. Owing both to the specificity and complexity of the disease, AERD patients should stay under regular care of well experienced referential medical centers to ensure that this asthma phenotype is dealt with effectively.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aspirin-exacerbated respiratory disease; Asthma control; Asthma control test; Asthma phenotype; Nonsteroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2015        PMID: 25820158     DOI: 10.1016/j.rmed.2015.02.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

Review 1.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

2.  Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.

Authors:  Whitney W Stevens; Anju T Peters; Annemarie G Hirsch; Cara M Nordberg; Brian S Schwartz; Dione G Mercer; Mahboobeh Mahdavinia; Leslie C Grammer; Kathryn E Hulse; Robert C Kern; Pedro Avila; Robert P Schleimer
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

Review 3.  Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.

Authors:  Whitney W Stevens; Robert P Schleimer
Journal:  Immunol Allergy Clin North Am       Date:  2016-09-13       Impact factor: 3.479

4.  Automated identification of an aspirin-exacerbated respiratory disease cohort.

Authors:  Katherine N Cahill; Christina B Johns; Jing Cui; Paige Wickner; David W Bates; Tanya M Laidlaw; Patrick E Beeler
Journal:  J Allergy Clin Immunol       Date:  2016-07-25       Impact factor: 10.793

5.  Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.

Authors:  Sharan J Shah; Waleed M Abuzeid; Anusha Ponduri; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; David Rosenstreich; Denisa Ferastraoaru; Elina Jerschow
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-30       Impact factor: 3.858

6.  Reply.

Authors:  Whitney W Stevens; Lydia Suh; Anju T Peters; Robert P Schleimer
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Nov - Dec

7.  MS4A2-rs573790 Is Associated With Aspirin-Exacerbated Respiratory Disease: Replicative Study Using a Candidate Gene Strategy.

Authors:  Gandhi F Pavón-Romero; Gloria Pérez-Rubio; Fernando Ramírez-Jiménez; Enrique Ambrocio-Ortiz; Elisé Bañuelos-Ortiz; Norma Alvarado-Franco; Karen E Xochipa-Ruiz; Elizabeth Hernández-Juárez; Beatriz A Flores-García; Ángel E Camarena; Luis M Terán; Ramcés Falfán-Valencia
Journal:  Front Genet       Date:  2018-09-11       Impact factor: 4.599

8.  The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease.

Authors:  Suzy A A Comhair; Grazyna Bochenek; Sara Baicker-McKee; Zeneng Wang; Tomasz Stachura; Marek Sanak; Jeffrey P Hammel; Stanley L Hazen; Serpil C Erzurum; Ewa Nizankowska-Mogilnicka
Journal:  Respir Res       Date:  2018-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.